The U.S. Health & Human Services Department (HHS) recommendation to reschedule cannabis from a Schedule I to a Schedule III drug1 will transform the cannabis industry and create new opportunities for banking and financial services providers. Robert Mann, Co-Founder & CEO of StandardC, noted that if approved, HHS’s recommendation to reschedule cannabis from Schedule I to Schedule III would be a crucial step, and the first at the Federal level, to improve the financial viability of the licensed cannabis industry in […]